Advertisement

Tumor Biology

, Volume 36, Issue 6, pp 4427–4432 | Cite as

The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer

  • Onder Yumrutas
  • Serdar Oztuzcu
  • Hakan Büyükhatipoglu
  • Ibrahim Bozgeyik
  • Esra Bozgeyik
  • Yusuf Ziya Igci
  • Haydar Bagis
  • M. Ozgur Cevik
  • M. Emin Kalender
  • Zeynep Eslik
  • Ahmet Arslan
Research Article

Abstract

Breast cancer is the most common malignancy predominantly affecting women. To date, numerous numbers of studies were reported novel genetic contributors with diagnostic, prognostic, and therapeutic potential for the breast carcinogenesis. However, the role of urotensin-II in breast carcinogenesis has not been elucidated yet. Urotensin-II is a somatostatin-like cyclic tiny peptide identified by its potent vasoconstrictor activity. Soon after its discovery, its involvement in many disease states as well as its expression in various tissues including the tumors have been demonstrated. Moreover, there is strong evidence that suggest urotensin-II as the significant contributor of angiogenesis as well as cell proliferation and tumor biology. In this study, enzyme-linked immunosorbent assay (ELISA) and restriction fragment length polymorphism analysis were used to evaluate plasma levels of urotensin-II and Thr21Met and Ser89Asn polymorphisms of UTS2 gene in breast cancer patients. In the present case-control study, we noticed a significant decrease in the levels of urotensin-II protein in the plasma of the breast cancer patients (p < 0.05). Also, Thr21Met polymorphism in the UTS2 gene was associated with the risk of developing breast cancer (p < 0.0001), whereas the genotype frequency of Ser89Asn was found to be similar in patients and controls (p > 0.05). In addition, we demonstrated the gradual decreasing of urotensin-II protein levels from TT and TM to MM genotypes. In conclusion, these results strongly suggest that urotensin-II could contribute to breast carcinogenesis and Thr21Met polymorphism can be an important risk factor in developing breast tumors.

Keywords

Breast cancer ELISA T21M polymorphism Urotensin-II 

Notes

Acknowledgments

This study was supported by a project from the Scientific Research Projects Management Unit of Adiyaman University.

Conflicts of interest

None

References

  1. 1.
    Miki Y, Swensen J, Shattuckeidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian-cancer susceptibility gene brca1. Science. 1994;266:66–71.CrossRefPubMedGoogle Scholar
  2. 2.
    Christodoulatos GS, Dalamaga M. Micro-RNAs as clinical biomarkers and therapeutic targets in breast cancer: Quo vadis? World J Clin Oncol. 2014;5:71–81.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    van de Vijver MJ. Molecular tests as prognostic factors in breast cancer. Virchows Arch. 2014;464:283–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602.CrossRefPubMedGoogle Scholar
  5. 5.
    Ames RS, Sarau HM, Chambers JK, Willette RN, Alyar NV, Romanic AM, et al. Human urotensin-ii is a potent vasoconstrictor and agonist for the orphan receptor gpr14. Nature. 1999;401:282.CrossRefPubMedGoogle Scholar
  6. 6.
    Okumus S, Igci YZ, Taskin T, Oztuzcu S, Gurler B, Eslik Z, et al. Association between thr21met and ser89asn polymorphisms of the urotensin-ii (uts2) gene, diabetes mellitus, and diabetic retinopathy. Curr Eye Res. 2012;37:921–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Ong KL, Lam KS, Cheung BM. Urotensin ii: its function in health and its role in disease. Cardiovascular drugs and therapy/sponsored by the. Int Soc Cardiovasc Pharmacother. 2005;19:65–75.Google Scholar
  8. 8.
    McDonald J, Batuwangala M, Lambert DG. Role of urotensin ii and its receptor in health and disease. J Anesth. 2007;21:378–89.CrossRefPubMedGoogle Scholar
  9. 9.
    Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y, et al. Expression of urotensin ii and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin ii. Peptides. 2003;24:301–6.CrossRefPubMedGoogle Scholar
  10. 10.
    Pehlivan Y, Gogebakan B, Oztuzcu S, Ozgen M, Cetin GY, Bayraktar R, et al. Association between thr21met and ser89asn polymorphisms of the urotensin ii gene and systemic sclerosis. J Rheumatol. 2012;39:106–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Oztuzcu S, Ulasli M, Pehlivan Y, Cevik MO, Cengiz B, Gogebakan B, et al. Thr21met (t21m) but not ser89asn (s89n) polymorphisms of the urotensin-ii (uts-ii) gene are associated with Behcet’s disease (bd). Peptides. 2013;42:97–100.CrossRefPubMedGoogle Scholar
  12. 12.
    Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, et al. Role of urotensin ii gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia. 2003;46:972–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Suzuki S, Wenyi Z, Hirai M, Hinokio Y, Suzuki C, Yamada T, et al. Genetic variations at urotensin ii and urotensin ii receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides. 2004;25:1803–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Spinazzi R, Albertin G, Nico B, Guidolin D, Di Liddo R, Rossi GP, et al. Urotensin-ii and its receptor (ut-r) are expressed in rat brain endothelial cells, and urotensin-ii via ut-r stimulates angiogenesis in vivo and in vitro. Int J Mol Med. 2006;18:1107.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Onder Yumrutas
    • 1
  • Serdar Oztuzcu
    • 2
  • Hakan Büyükhatipoglu
    • 3
  • Ibrahim Bozgeyik
    • 1
  • Esra Bozgeyik
    • 2
  • Yusuf Ziya Igci
    • 2
  • Haydar Bagis
    • 4
  • M. Ozgur Cevik
    • 4
  • M. Emin Kalender
    • 3
  • Zeynep Eslik
    • 2
  • Ahmet Arslan
    • 2
  1. 1.Department of Medical Biology, Faculty of MedicineAdiyaman UniversityAdiyamanTurkey
  2. 2.Department of Medical Biology, Faculty of MedicineUniversity of GaziantepGaziantepTurkey
  3. 3.Department of Medical Oncology, Faculty of MedicineUniversity of GaziantepGaziantepTurkey
  4. 4.Department of Medical Genetics, Faculty of MedicineAdiyaman UniversityAdiyamanTurkey

Personalised recommendations